Evidence mapPaperPMID 34706972Full record

ArticleNeurology2021

Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability.

Stephen A Johnson, Kamal Shouman, Shahar Shelly, Paola Sandroni, Sarah E Berini, P James B Dyck, Ernest Matthew Hoffman, Jay Mandrekar, Zhiyv Niu, Christopher J Lamb and 7 more

Open access · greenAbstract read
In one paragraph

Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Small Fiber Neuropathy in Burning Mouth Syndrome: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Sarcoidosis-related small fiber neuropathy: Focus on fatigue, pain, restless legs syndrome, and cognitive function.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Stephen A JohnsonFrom the Mayo Clinic, Rochester, MN.
Kamal ShoumanFrom the Mayo Clinic, Rochester, MN.
Shahar ShellyFrom the Mayo Clinic, Rochester, MN.ORCID 0000-0002-3585-1687
Paola SandroniFrom the Mayo Clinic, Rochester, MN.
Sarah E BeriniFrom the Mayo Clinic, Rochester, MN.
P James B DyckFrom the Mayo Clinic, Rochester, MN.ORCID 0000-0003-0212-8254
Ernest Matthew HoffmanFrom the Mayo Clinic, Rochester, MN.ORCID 0000-0001-7293-8290
Jay MandrekarFrom the Mayo Clinic, Rochester, MN.
Zhiyv NiuFrom the Mayo Clinic, Rochester, MN.
Christopher J LambFrom the Mayo Clinic, Rochester, MN.
Phillip A LowFrom the Mayo Clinic, Rochester, MN.
Wolfgang SingerFrom the Mayo Clinic, Rochester, MN.
Michelle L MauermannFrom the Mayo Clinic, Rochester, MN.
John MillsFrom the Mayo Clinic, Rochester, MN.
Divyanshu DubeyFrom the Mayo Clinic, Rochester, MN.
Nathan P StaffFrom the Mayo Clinic, Rochester, MN.
Christopher J KleinFrom the Mayo Clinic, Rochester, MN. klein.christopher@mayo.edu.ORCID 0000-0002-4012-8856
Mayo Clinic in Arizona · US

Funding

NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere are limited population-based data on small fiber neuropathy (SFN). We wished to determine SFN incidence, prevalence, comorbid conditions, longitudinal impairments, and disabilities.

methodsTest-confirmed patients with SFN in Olmsted, Minnesota, and adjacent counties were compared 3:1 to matched controls (January 1, 1998-December 31, 2017).

resultsNinety-four patients with SFN were identified, with an incidence of 1.3/100,000/y that increased over the study period and a prevalence of 13.3 per 100,000. Average follow-up was 6.1 years (0.7-43 years), and mean onset age was 54 years (range 14-83 years). Female sex (67%), obesity (body mass index mean 30.4 vs 28.5 kg/m DISCUSSION: Isolated SFN is uncommon but increasing in incidence. Most patients do not develop major neurologic impairments and disability but have multiple comorbid conditions, including cardiovascular ischemic events, and increased mortality from SFN onsets. Development of large fiber involvements and diabetes are common over time. Targeted testing facilitates interventional therapies for diabetes but also rheumatologic and rare genetic forms.

Indexed as

Peripheral Nervous System DiseasesSjogren's SyndromeSmall Fiber NeuropathyAdolescentAdultAgedAged, 80 and overFemaleHumansIncidenceMiddle AgedPrevalenceYoung Adult

Identifiers

PMID34706972
PMCPMC8641968
OpenAlexW3208502226

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.